These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

226 related items for PubMed ID: 37728795

  • 1. Cost-effectiveness of granulocyte colony-stimulating factors (G-CSFs) for the prevention of febrile neutropenia (FN) in patients with cancer.
    Aapro MS, Chaplin S, Cornes P, Howe S, Link H, Koptelova N, Mehl A, Di Palma M, Schroader BK, Terkola R.
    Support Care Cancer; 2023 Sep 20; 31(10):581. PubMed ID: 37728795
    [Abstract] [Full Text] [Related]

  • 2. Cost-Effectiveness Analysis of Prophylaxis Treatment Strategies to Reduce the Incidence of Febrile Neutropenia in Patients with Early-Stage Breast Cancer or Non-Hodgkin Lymphoma.
    Fust K, Li X, Maschio M, Villa G, Parthan A, Barron R, Weinstein MC, Somers L, Hoefkens C, Lyman GH.
    Pharmacoeconomics; 2017 Apr 20; 35(4):425-438. PubMed ID: 27928760
    [Abstract] [Full Text] [Related]

  • 3. Primary Prophylaxis With Biosimilar Filgrastim for Patients at Intermediate Risk for Febrile Neutropenia: A Cost-Effectiveness Analysis.
    Li E, Mezzio DJ, Campbell D, Campbell K, Lyman GH.
    JCO Oncol Pract; 2021 Aug 20; 17(8):e1235-e1245. PubMed ID: 33793342
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Primary vs secondary prophylaxis with pegfilgrastim for the reduction of febrile neutropenia risk in patients receiving chemotherapy for non-Hodgkin's lymphoma: cost-effectiveness analyses.
    Hill G, Barron R, Fust K, Skornicki ME, Taylor DC, Weinstein MC, Lyman GH.
    J Med Econ; 2014 Jan 20; 17(1):32-42. PubMed ID: 24028444
    [Abstract] [Full Text] [Related]

  • 6. Cost-effectiveness of prophylactic granulocyte colony-stimulating factor for febrile neutropenia in breast cancer patients receiving FEC-D.
    Lee EK, Wong WW, Trudeau ME, Chan KK.
    Breast Cancer Res Treat; 2015 Feb 20; 150(1):169-80. PubMed ID: 25694355
    [Abstract] [Full Text] [Related]

  • 7. Effectiveness of biosimilar filgrastim vs. original granulocyte colony-stimulating factors in febrile neutropenia prevention in breast cancer patients.
    Puértolas I, Frutos Pérez-Surio A, Alcácera MA, Andrés R, Salvador MDT.
    Eur J Clin Pharmacol; 2018 Mar 20; 74(3):315-321. PubMed ID: 29152672
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States.
    Lyman G, Lalla A, Barron R, Dubois RW.
    Curr Med Res Opin; 2009 Feb 20; 25(2):401-11. PubMed ID: 19192985
    [Abstract] [Full Text] [Related]

  • 10. Cost-effectiveness of prophylaxis treatment strategies for febrile neutropenia in patients with recurrent ovarian cancer.
    Fust K, Li X, Maschio M, Barron R, Weinstein MC, Parthan A, Walli-Attaei M, Chandler DB, Lyman GH.
    Gynecol Oncol; 2014 Jun 20; 133(3):446-53. PubMed ID: 24657302
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The impact of primary prophylaxis with granulocyte colony-stimulating factors on febrile neutropenia during chemotherapy: a systematic review and meta-analysis of randomized controlled trials.
    Wang L, Baser O, Kutikova L, Page JH, Barron R.
    Support Care Cancer; 2015 Nov 20; 23(11):3131-40. PubMed ID: 25821144
    [Abstract] [Full Text] [Related]

  • 13. Comparison of effectiveness of biosimilar filgrastim (Nivestim™), reference Amgen filgrastim and pegfilgrastim in febrile neutropenia primary prevention in breast cancer patients treated with neo(adjuvant) TAC: a non-interventional cohort study.
    Brito M, Esteves S, André R, Isidoro M, Moreira A.
    Support Care Cancer; 2016 Feb 20; 24(2):597-603. PubMed ID: 26111956
    [Abstract] [Full Text] [Related]

  • 14. Comparative effectiveness of granulocyte colony-stimulating factors to prevent febrile neutropenia and related complications in cancer patients in clinical practice: A systematic review.
    Mitchell S, Li X, Woods M, Garcia J, Hebard-Massey K, Barron R, Samuel M.
    J Oncol Pharm Pract; 2016 Oct 20; 22(5):702-16. PubMed ID: 26769697
    [Abstract] [Full Text] [Related]

  • 15. Cost-effectiveness of pegfilgrastim versus filgrastim for prevention of chemotherapy-induced febrile neutropenia in patients with lymphoma: a systematic review.
    Gebremariam GT, Fentie AM, Beyene K, Sander B, Gebretekle GB.
    BMC Health Serv Res; 2022 Dec 30; 22(1):1600. PubMed ID: 36585648
    [Abstract] [Full Text] [Related]

  • 16. Cost-effectiveness of granulocyte colony-stimulating factor prophylaxis for febrile neutropenia in breast cancer in the United Kingdom.
    Whyte S, Cooper KL, Stevenson MD, Madan J, Akehurst R.
    Value Health; 2011 Jun 30; 14(4):465-74. PubMed ID: 21669371
    [Abstract] [Full Text] [Related]

  • 17. Cost-effectiveness of febrile neutropenia prevention with primary versus secondary G-CSF prophylaxis for adjuvant chemotherapy in breast cancer: a systematic review.
    Younis T, Rayson D, Jovanovic S, Skedgel C.
    Breast Cancer Res Treat; 2016 Oct 30; 159(3):425-32. PubMed ID: 27572552
    [Abstract] [Full Text] [Related]

  • 18. [Pegfilgrastim vs filgrastim in primary prophylaxis of febrile neutropenia in patients with breast cancer after chemotherapy: a cost-effectiveness analysis for Germany].
    Sehouli J, Goertz A, Steinle T, Dubois R, Plesnila-Frank C, Lalla A, von Minckwitz G.
    Dtsch Med Wochenschr; 2010 Mar 30; 135(9):385-9. PubMed ID: 20180162
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.